Hepatitis C virus inhibitors

US9326973B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Piyasena Hewawasam · Middletown, US
• John F. Kadow · Wallingford, US
• Omar D. Lopez · Wallingford, US
• Nicholas A. Meanwell · East Hampton, US
• Yong Tu · Cheshire, US
• Alan Xiangdong Wang · Guilford, US
• Ningning Xu · Lawrenceville, US
• Samayamunthula Venkata Satya Arun Kumar Gupta · Bengaluru, IN
• Pothukanuri Srinivasu · Bengaluru, IN
• Indasi Gopi Kumar · Bengaluru, IN
• Ponugupati Suresh Kumar · Bengaluru, IN
• Makonen Belema · North Haven, US
• Robert A. Fridell · Wallingford, US
• Min Gao · 安丰镇, CN
• Julie A. Lemm · Durham, US
• Donald O'Boyle · Killingworth, US
• Jin-Hua Sun · North Haven, US
• Chunfu Wang · Cheshire, US
• Ying Wang · Chengdu, CN

Key dates

• Filing date: Jan 7, 2013
• Grant date: May 3, 2016
• Expiry date: Oct 23, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/113
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.